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doi:10.1016/j.ejvs.2010.11.033Abstract Objectives: The study aimed to evaluate a wide range of apoptotic markers in the
vein wall of patients with superficial chronic venous disease (SCVD) compared with normal
veins.
Design: This was an observational study.
Methods: Vein specimens were obtained from 19 patients suffering from SCVD. From each
patient, a specimen of the proximal part of the great saphenous vein (GSV), a specimen of
the distal part of the vein and a specimen of a varicose tributary were obtained. Immunohis-
tochemical analysis was used to localise the expression of BAX, p53, Caspase 3, BCL-2, BCL-6,
BCL-xs, BCL-xl and Ki-67. Vein specimens from 10 healthy GSVs were used as controls.
Results: Saphenous vein specimens from patients with SCVD showed increased BAX, Caspase 3,
BCL-xl and BCL-xs (p < 0.01 for all) and Ki-67 (p Z 0.02) compared with healthy GSVs. In the
venous disease group, GSV specimens from the distal ankle area showed increased BAX
(p < 0.01) and BCL-xs (pZ 0.031) compared with varicose tributaries specimens, which subse-
quently showed increased BAX (p Z 0.044), Caspase 3 (p Z 0.028) and BCL-xs (p Z 0.037)
compared with specimens from the proximal GSV. In addition, in the venous disease group,
specimens from distal GSV showed increased BAX (p < 0.01), Caspase 3 (p Z 0.019) and
BCL-xs (p Z 0.014) compared with the proximal GSV.
Conclusion: Varicose veins exhibit increased apoptotic activity, by means of increased BAX,
Caspase 3, BCL-xl and BCL-xs, compared with normal veins. Patients with varicose vein disease
show increased apoptosis in the distal saphenous trunk compared with the proximal saphenous
trunk, suggesting an association between chronic venous hypertension and apoptosis.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.enis Str., 15562 Holargos, Greece. Tel.: þ30 2106561429; fax: þ30 2107707574.
(K. Filis).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
534 K. Filis et al.The processes leading to varicose veins remain unclear. Tissue preparationThere is some evidence that altered apoptotic mechanisms
may contribute to this. A number of studies have demon-
strated programmed cell death in vessels that remodel
postnatally.1,2 Increased apoptotic activity within the
media of varicose veins has been shown by Bujan et al.,
while Ascher et al. concluded that down-regulation of
apoptosis occurred in primary varicose veins.3,4 More
recently, Urbanek et al. showed that during varicose vein
development, activation of apoptosis is related to the early
stages of venous incompetence, while down-regulation of
the smooth muscle cell apoptosis leads to structural
changes.5 Down-regulation of apoptosis in the media layer
of varicose veins was also shown by Ducasse et al., who
concluded that deregulation of the intrinsic apoptotic
pathway may be among the causes of the disease.6
However, one of the most pressing questions to be
answered is whether deregulated apoptosis is the cause or
the effect of varicose vein formation.
It is known that apoptosis is the cause of ‘normal’ cell
death. In this study, we evaluated a series of mediators
regulating the apoptotic pathway and cell proliferation in
human surgical specimens of varicose veins and healthy
veins of the lower limbs. To determine if apoptotic
mechanisms depend on the late effect of long-standing
venous hypertension, we evaluated the apoptotic markers
in three different anatomical locations: the proximal part
of the GSV, a GSV tributary of the calf and the distal part
of GSV.
Materials and Methods
Patients
Lower limb vein specimens were obtained from two groups
of patients. Group I (venous disease group) consisted of 19
patients (10 women) suffering primary superficial venous
disease, at stages C2, EP, AS and PR without history of
superficial vein thrombosis. Group II (control group) con-
sisted of 10 patients (three women, mean age 63 years),
who underwent distal GSV excision for using it as a graft in
cardiac bypass. Group I (mean age 48 years) had a mean
disease duration of 12 years (from 4 to 25 years, median 8.5
years), and a preoperative lower-limb duplex ultrasound
assessment confirming the extent of venous reflux in the
GSV. No evidence of current or previous deep or superficial
venous thrombosis was found. Control patients underwent
preoperative (before cardiac bypass) venous duplex ultra-
sonography scan as quality control for the vein segment to
be used as a graft during aortocoronary bypass grafting and
to confirm the absence of deep or superficial venous
thrombosis.
Patients in group I underwent stripping of the GSV from
the ankle to the saphenofemoral junction and with excision
of tributaries. Before saphenous vein stripping, a 2-cm vein
segment was excised from the saphenofemoral junction
and the GSV at the ankle. Another 2-cm vein segment was
excised from a calf varicosity. In patients of group II, the
distal 2 cm of the GSV was used as control vein.
Ethical approval for the study was obtained from the
University of Athens Medical School.All vein specimens were divided into two portions along the
longitudinal axis. The specimens collected were fixed in
10% neutral-buffered solution containing approximately 4%
formaldehyde for 24 h, and embedded in paraffin for
conventional histology and immunohistochemistry.
Histology
Routine haematoxylin and eosin staining was performed for
histological evaluation of the specimens. Gomori’s one-step
trichrome staining was used to indentify increased collag-
enous connective fibres and to differentiate between
collagen and smooth muscle fibres in both normal and
varicose vein specimens. Verhoeff’s elastic tissue stain
(with van Gieson’s stain to counterstain) was performed to
assess the pathological changes in the elastin network in all
the veins included in the study. Histology was performed for
confirmation that the sections used for immunohistochem-
ical analysis contained the classical findings of varicose
veins and as well as those of healthy veins in group II.
Immunohistochemistry
Antibodies
For immunohistochemical analysis, the following antibodies
were used: BCL-6 (clone: PG-B6p) mouse monoclonal anti-
body (Dako, Kalifronas,Athens,Greece) inadilution1:10; p53
(clone: DO-7) mouse monoclonal antibody (Dako, Kalifronas,
Athens, Greece) in a dilution of 1:50; Ki-67 (clone:MIB-1)
mouse monoclonal antibody (Dako, Kalifronas, Athens,
Greece) in a 1: 50 dilution; BCL-2 (clone:BCL-2/100/D5)
mouse monoclonal antibody (NCL-L-BCL2-Novocastra,Mer-
anini Diagnostics, Athens, Greece) in a 1:50 dilution; Caspase
3 (clone:3CSPO3) mouse monoclonal antibody (Neomarkers,
Bioanalytica, Athens, Greece) in dilution 1:50; BAX (clo-
ne:930Rb) rabbit polyclonal antibody (Santa-Cruz Biotech-
nology, Bioanalytica, Athens, Greece) in 1:200 dilution; BCL-
xs (clone: PC89) mouse monoclonal antibody (Calbiochem,
Chemilab, Athens, Greece) in 1:100 dilution; and BCL-xl
(clone:H-62) rabbit polyclonal antibody (Santa-Cruz Biotech-
nology, Bioanalytica, Athens, Greece) in 1:100 dilution.
Method
Immunohistochemistry was performed according to an
indirect streptavidinebiotineperoxidase method. In brief,
5-mm paraffin sections were placed on poly-L-lysine-coated
slides, dewaxed, rehydrated and incubated for 30 min with
0.3% hydrogen peroxide to quench the endogenous peroxi-
dase activity. Unmasking of the related proteins was carried
out. The sections were incubated with the primary antibody
at a 1:50 dilution at 4 C overnight. Biotin-conjugated
secondary antibody was added at a 1:200 dilution for 1 h at
room temperature. The next stage comprised 30-min
incubation in StrepteAB complex (1:100 stock biotin solu-
tion, 1:100 stock streptavidinehyperoxidase solution)
(Dako, Kalifronas, Athens, Greece). For colour develop-
ment, we used 3,30-diaminobenzidine tetrahydrochloride
(DAB, Sigma-Hellas, Athens, Greece) and haematoxylin as
a counterstain.
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Two independent observers carried out the slide examina-
tion. Inter-observer disagreement was tested with the
paired t-test and was non-significant (p Z 0.92). The
staining pattern was considered positive only if a cyto-
plasmic signal was discerned.
Images were taken using a Zeiss Axiolab microscope (Carl
Zeiss GmbH, Jena, Germany) with a mechanical stage, fitted
to a Sony-Iris charge-coupled device (CCD) video camera
(Sony Corp., Tokyo, Japan). The camera was connected to
a computer with image analysis software. Slides were
examined at high-power magnification (400). A first elab-
oration of digital images was done by using Image Scan Pro
software (Science GmbH, Erkrath, Germany). Further eval-
uation was made via Color Estimation v.2.0, a specific
application developed at the Department of Pathology of
Athens University written in Microsoft Visual Basic 5.0
(Microsoft Corp., Redmond, WA, USA) for the evaluation of
immunohistochemical colour images. The stained cells were
selected manually, but the measurement of staining inten-
sity was performed according to the mean value of density,
whichwas calculated automatically. Both observers used the
same software.
The expression of proteins was evaluated according to
staining intensity and immunocytochemical distribution e
cytoplasmic and nuclear staining. A semiquantitative
assessment of positive cells was initially performed (no
staining, minimal staining (1e3%), moderate staining
(3e50%) and maximal staining (50e100%)) for descriptive
reasons. Cells that stained positive for the examined anti-
bodies in the intima, media, adventitia and the vasa vaso-
rum were counted at 400 magnification and quantified in
10 random fields per section. Five sections per specimen
were evaluated, resulting in 50 observations for each
specimen per patient. Results for each apoptotic marker
were presented as the mean value of the percentage of
positive cells/negative cells.
Statistics
Differences in the expression of the studied factors among
the predefined groups were tested by a KruskaleWallis (KW)
test and comparisons in post hoc analysis between two
groups were carried out by the ManneWhitneyeU test (MW)
test.
Results
Histology
Gomori’s trichrome staining showed decreased collagen
matrix in varicose veins, as compared with healthy veins.
Gomori’s trichrome staining showed a minimal decrease in
collagen matrix in the proximal part of the GSV in
comparison with the distal part of the GSV, where the
collagen matrix was more decreased than in normal and
proximal parts (Fig. 1).
Degradation of the elastin network was demonstrated in
varicose veins by means of van Gieson’s elastic staining.
Smooth muscle cells (SMCs) of varicose vein specimens
were enlarged and appeared to have lost their elongatedmorphology. Van Gieson’s elastic stain showed a minimal
degradation in the proximal part of the GSV in comparison
with the distal part of the GSV where there was a moderate
degradation (Fig. 1).
Immunohistochemical results in group I
The age in group I (mean 48 years) was less than that in
group II (mean 63 years). This is discussed below. Compar-
isons among groups concerning the protein expressions of
BAX, p53, Caspase 3, BCL-2, BCL-6, BCL-xs, BCL-xl and Ki-67
were carried out.
BAX showed cytoplasmic expression in varicose veins,
particularly in the media and intima (Fig. 2). p53 showed no
or a minimal expression in veins. Caspase 3 showed a cyto-
plasmic expression mainly in the distal part of the GSV.
BCL-2 and BCL-6 showed no expression and ki-67 showed
a minimal nuclear expression mainly in the distal part of the
GSV too. BCL-xs expression was found to localise only to the
cytoplasm with a granular pattern, particularly in the SMCs
(Fig. 2), whereas BCL-xl showed a minimal cytoplasmic
expression, mainly in varicose veins.
There were significant differences in BAX, p53, Caspase 3,
BCL-xs, BCL-xl and Ki-67 between the proximal, the varicose
tributary and thedistal part ofGSV (KruskaleWallis test, Table
1). BAX and BCL-xs expressions were significantly higher in the
distal part of the GSV compared with the varicosity tributary
(ManneWhitneyeU test, Table 2). BAX, Caspase 3 and BCL-xs
expressionsweresignificantlyhigher in thevaricosity tributary
compared with the proximal part of the GSV in post hoc anal-
ysis (ManneWhitneyeU test,Table2).BAX,Caspase3andBCL-
xs expressions were significantly higher in the distal compared
with the proximal part of the GSV (ManneWhitneyeU test,
Table 2).
Immunohistochemical results in group II
Expression of BAX, p53, Caspase 3, BCL-2, BCL-6, BCL-xs,
BCL-xl and Ki-67 were not different between the proximal
and the distal parts of the GSV.
Comparison of immunochemical results between
groups I and II
There were significant differences between the two groups
for the expression of BAX, Caspase 3, BCL-xs, BCL-xl and
Ki-67 (Table 3). BAX caspase 3, BCL-xs and BCL-xl expression
in the distal part of the GSV in group I was increased
compared with the control group (p < 0.01 for all). Ki-67
expression was also increased (p Z 0.02) in group I
compared with group II.
Discussion
The involvement of the apoptotic mechanism constitutes
a novel approach regarding the investigation of the patho-
genesis and development of varicose veins. The results
obtained from studies published in the last 10 years report
a conflicting range of up- and down-regulation of apoptotic
activity in primary varicose veins.
Figure 1 A. Normal vein, Gomori’s stain (magnification 100). B. Proximal part of GSV with Gomori’s stain (magnification 100).
C. Gomori’s stain in varicose vein tissue (magnification 100). D. Distal part of GSV with Gomori’s stain (magnification 100).
E. Normal vein with elastin staining (magnification 100). F. Proximal part of GSV with elastin stain (magnification 100). G. Elastin
stain in varicose vein tissue (magnification 100). H. Distal part of GSV with elastin stain (magnification 100).
536 K. Filis et al.Our study shows that apoptotic deregulation is present
in primary varicose veins. Among a series of apoptotic
markers studied, BAX, Caspase 3, BCL-xs and Ki-67
expressions were increased in the GSVs of patients suffering
primary varicose veins compared with healthy GSVs. This
demonstrates a relationship between these factors, but wecannot conclude that apoptotic deregulation is the main
cause of the disease. We showed that there is an increase in
the apoptotic activity in the distal part of GSV compared
with the proximal part (mainly BAX and secondary Caspase
3 and BCL-xs) in varicose veins, which may be due to venous
hypertension in these venous segments. We also found that
Figure 2 Immunohistochemical (IHC) analysis of BAX and BCL-xs in proximal part of GSV (A,D) in varicose vein tissue (B,E) and
distal part of GSV (C,F) at 200 magnification, respectively. Short white arrows: fibroblasts, Long white arrows: inflammatory cells,
Short black arrows: endothelial cells, Long black arrows: smooth muscle cells.
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saphenous trunks.
We selected measurement of the expression of BAX
protein and BCL-xs as promoters of apoptosis, and from the
anti-apoptotic value divided the expression of BCL-2 proper
andBCL-xl. BAX is a protein of theBCL-2 family that acts as an
inducer of apoptosis by competing with BCL-2 proper. BAX,
upon activation, inserts into the outer mitochondrialTable 1 Comparisons of apoptotic marker expression in patie
anatomic locations (proximal, tributary, distal) of the superficial v
the saphenofemoral junction. Tributary: a part 2 cm- of a GSV tri
ankle.
Venous disease group Proximal GSV
BAX 6.0 (2.7)
p53 0 (0)
caspase 3 1.5 (1.2)
BCL-2 0 (0)
BCL-6 0 (0)
BCL-xs 3.3 (2.1)
BCL-xl 1.6 (4.1)
Ki-67 1.3 (1.3)membrane causing changes in the permeability and thereby
triggering apoptosis7; however, it is also a downstream
effector of the tumour suppressor gene, p53. BAX expression
can activate a common pathway of apoptosis that is either
caspase-dependent or caspase-independent.8 Enhanced BAX
expression in varicose veins compared with normal veins was
one of the main results in this study. In addition, the distal
part of the GSV showed increased BAX compared with thents with varicose veins (group I) among the three different
enous system. Proximal: the -2 cm- proximal part of GSV near
butary of the calf. Distal: the -2 cm- distal part of GSV at the
Tributary Distal GSV KW test p
8.9 (4.7) 21.8 (9.0) <0.01
0.1 (0.3) 0.3 (1.1) NS
2.3 (0.9) 3.1 (2.1) 0.014
0 (0) 0 (0) NS
0 (0) 0 (0) NS
4.4 (2.1) 6.9 (4.8) <0.01
6.3 (11.0) 3.6 (6.4) NS
1.7 (1.2) 1.9 (1.3) NS
Table 2 Comparisons of apoptotic marker expression in patients with varicose veins (group I) between two different anatomic
locations of the superficial venous system. Proximal: the -2 cm- proximal part of GSV near the saphenofemoral junction.
Tributary: a part 2 cm- of a GSV tributary of the calf. Distal: the -2 cm- distal part of GSV at the ankle.
Venous disease group Proximal GSV Tributary MW-U test p
BAX 6.0 (2.7) 8.9 (4.7) 0.044
Caspase 3 1.5 (1.2) 2.3 (0.9) 0.028
BCL-xs 3.3 (2.1) 4.4 (2.1) 0.037
Tributary Distal GSV MW-U test p
BAX 8.9 (4.7) 21.8 (9.0) <0.01
Caspase 3 2.3 (0.9) 3.1 (2.1) NS
BCL-xs 4.4 (2.1) 6.9 (4.8) 0.031
Proximal GSV Distal GSV MW-U test p
BAX 6.0 (2.7) 21.8 (9.0) <0.01
Caspase 3 1.5 (1.2) 3.1 (2.1) 0.019
BCL-xs 3.3 (2.1) 6.9 (4.8) 0.014
538 K. Filis et al.tributary, and the tributary showed increased BAX compared
with the proximal GSV part. This finding is similar to the study
of Urbanek et al.,5 who showed increased BAX in the distal
part of the vein, although they do not report findings for the
saphenous tributaries. By contrast, Ascher et al. found that
immunoreactivity of BAX was significantly higher in the
normal veins.9
We could not detect BCL-2 expression in our specimens.
Ascher et al. as well, reported lack of immunopositivity for
BCL-2 in varicose veins and concluded that this may be due
to the lack of specificity of the antibody used to cell types
in the vein tissue. However, other investigators found
a significant BCL-2 expression, which was enhanced in the
distal part of the GSV compared with the proximal part.9
BCL-6 is a protein encoded by the human proto-onco-
gene BCL-6 that acts as a sequence-specific repressor of
transcription. Several studies aimed to identify the possible
targets of the repressive effects of BCL-6 in the apoptotic
process. The results obtained from these studies suggest
that BCL-6 may regulate apoptosis by repressing the
expression of programmed cell death-2 gene and p53
tumour suppressor genes.10,11 As BCL-6 nuclear protein is
expressed in a variety of tissues, the down-regulation of
expression of this anti-apoptotic gene may also contribute
to the development of varicose vein disease.12 In our study,
we could not detect any positive BCL-2 staining in either
group, but only a weak BCL-6 staining in healthy saphenous
veins (0.2 cells per field). BCL-xl is a mitochondrialTable 3 Comparisons between groups I and II for the expressio
-2 cm- distal part of GSV at the ankle.
Distal GSV Venous disease group
BAX 21.8 (9.0)
p53 0.3 (1.1)
Caspase 3 3.1 (2.1)
BCL-2 0 (0)
BCL-6 0 (0)
BCL-xl 6.9 (4.8)
BCL-xs 3.6 (6.4)
Ki-67 1.9 (1.3)transmembrane member of BCL-2 family proteins that
exhibits anti-apoptotic properties.13 By contrast, BCL-xs
expresses pro-apoptotic activities such as BAX in a complex
manner, which is still largely unknown.14 Both these
markers were increased in patients with SCVD compared
with normal patients. Especially, BCL-xs expression was
increased in the distal part of the GSV compared with
tributaries, as well as increased in tributaries compared
with the proximal part of the GSV.
Caspases are a family of cysteine proteases, which are
involved in the execution phase of apoptosis.15 In the
present study, we observed a significant difference in
Caspase 3 immunopositivity between groups I and II. This
finding suggests an active apoptotic state in varicose veins.
However, the results obtained from the comparison of the
anatomic locations did not differ significantly.
p53 is a tumour suppressor gene important for the
regulation of cell cycle that, once activated in response to
various stress stimuli, will either induce a cell cycle arrest
to allow repair and survival or apoptosis to discard the
damaged cell.16 p53 examination was done in our study in
order to investigate a possible link between low oxygen
tension, which is observed in varicose vein disease, and p53
overexpression as a response to hypoxia. Although a rela-
tionship between p53 and hypoxia has been shown by
Michiels et al. and Hammond et al.,17,18 our results were
not supportive of increased p53 expression in group I
compared with group II. Expression of p53 was found only inn of apoptotic markers at the distal part of GSV. Distal: the
Control group MW-U test p
2.0 (2.0) <0.01
0 (0) NS
0 (0) <0.01
0 (0) NS
0.2 (0.4) NS
1.2 (1.5) <0.01
1.4 (3.0) <0.01
0.2 (0.4) 0.02
Apoptotic Mechanisms in Varicose Vein Disease 539the tributary and the distal GSV of group II, in this study.
Urbanek et al. also found increased p53 expression in the
distal GSV in young patients.5 These authors suggested that
elderly patients show increased structural vein wall
changes, and, hence, p53 expression is not evident. This is
a very useful piece of information to explain why some of
the apoptotic markers (such as p53) in our study and in
others are not expressed.
Ki-67 antigen is an excellent marker associated with cell
proliferation. Previous studies report that remodelling of
varicose vein wall is associated with smooth muscle cell
hypertrophy.19 Furthermore, Bujan et al. found an increased
number of apoptotic cells in the proximal part of varicose
veins associated with hypertrophic areas.3 The comparison
between group I and group II in our study unveiled increased
expression of Ki-67.
In thepresent study, theageof group Iwas43years and the
sex distribution was women to men: 5/4. Female sex and
advanced age are known factors for SCVD, although obesity
and number of pregnancies are the strongest contributing
factors for thedisease.20 Although, ageand sexdistribution in
our study seems physiological, for an SCVD group, this
differed from group II, which involved more elderly patients
with amale to female ratio of 7:3.Our control groupconsisted
of patientswith normalGSVduplex ultrasound from the ankle
level to the saphenofemoral junction, and histological eval-
uation did not reveal any vein wall pathology. However, the
limitation in thepresent study is that theunknownassociation
of apoptosis and age or gender, either in normal veins or in
veins with SCVD could possibly affect our results.
We conclude that that varicose veins are characterised by
increasedveinwallapoptosis,which isofgreatermagnitude in
the distal GSV where venous pressures are higher. As this is an
observational study, the association we have found between
venous disease and increased apoptosis does not indicate the
role that apoptosis plays in thedevelopment of varicoseveins.
Further research is required to investigate this point.
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